ID   XRP2_HUMAN              Reviewed;         350 AA.
AC   O75695; Q86XJ7; Q9NU67;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   28-JAN-2026, entry version 212.
DE   RecName: Full=Protein XRP2;
GN   Name=RP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS RP2 SER-6 DEL AND HIS-118.
RC   TISSUE=Brain;
RX   PubMed=9697692; DOI=10.1038/1214;
RA   Schwahn U., Lenzner S., Dong J., Feil S., Hinzmann B., van Duijnhoven G.,
RA   Kirschner R., Hemberger M., Bergen A.A.B., Rosenberg T., Pinckers A.J.L.G.,
RA   Fundele R., Rosenthal A., Cremers F.P.M., Ropers H.-H., Berger W.;
RT   "Positional cloning of the gene for X-linked retinitis pigmentosa 2.";
RL   Nat. Genet. 19:327-332(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [6]
RP   MYRISTOYLATION AT GLY-2, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=25255805; DOI=10.1038/ncomms5919;
RA   Thinon E., Serwa R.A., Broncel M., Brannigan J.A., Brassat U., Wright M.H.,
RA   Heal W.P., Wilkinson A.J., Mann D.J., Tate E.W.;
RT   "Global profiling of co- and post-translationally N-myristoylated proteomes
RT   in human cells.";
RL   Nat. Commun. 5:4919-4919(2014).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [8]
RP   CHARACTERIZATION OF VARIANTS RP2 SER-6 DEL AND HIS-118, MYRISTOYLATION AT
RP   GLY-2, PALMITOYLATION AT CYS-3, MUTAGENESIS OF GLY-2 AND CYS-3, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=10942419; DOI=10.1093/hmg/9.13.1919;
RA   Chapple J.P., Hardcastle A.J., Grayson C., Spackman L.A., Willison K.R.,
RA   Cheetham M.E.;
RT   "Mutations in the N-terminus of the X-linked retinitis pigmentosa protein
RT   RP2 interfere with the normal targeting of the protein to the plasma
RT   membrane.";
RL   Hum. Mol. Genet. 9:1919-1926(2000).
RN   [9]
RP   FUNCTION, CHARACTERIZATION OF VARIANTS RP2 SER-6 DEL AND HIS-118, AND
RP   INTERACTION WITH ARL3.
RX   PubMed=11847227; DOI=10.1074/jbc.m200128200;
RA   Bartolini F., Bhamidipati A., Thomas S., Schwahn U., Lewis S.A.,
RA   Cowan N.J.;
RT   "Functional overlap between retinitis pigmentosa 2 protein and the tubulin-
RT   specific chaperone cofactor C.";
RL   J. Biol. Chem. 277:14629-14634(2002).
RN   [10]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12417528; DOI=10.1093/hmg/11.24.3065;
RA   Grayson C., Bartolini F., Chapple J.P., Willison K.R., Bhamidipati A.,
RA   Lewis S.A., Luthert P.J., Hardcastle A.J., Cowan N.J., Cheetham M.E.;
RT   "Localization in the human retina of the X-linked retinitis pigmentosa
RT   protein RP2, its homologue cofactor C and the RP2 interacting protein
RT   Arl3.";
RL   Hum. Mol. Genet. 11:3065-3074(2002).
RN   [11]
RP   IDENTIFICATION IN A COMPLEX WITH ARL3 AND UNC119.
RX   PubMed=18588884; DOI=10.1016/j.febslet.2008.05.053;
RA   Veltel S., Kravchenko A., Ismail S., Wittinghofer A.;
RT   "Specificity of Arl2/Arl3 signaling is mediated by a ternary Arl3-effector-
RT   GAP complex.";
RL   FEBS Lett. 582:2501-2507(2008).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20106869; DOI=10.1093/hmg/ddq012;
RA   Evans R.J., Schwarz N., Nagel-Wolfrum K., Wolfrum U., Hardcastle A.J.,
RA   Cheetham M.E.;
RT   "The retinitis pigmentosa protein RP2 links pericentriolar vesicle
RT   transport between the Golgi and the primary cilium.";
RL   Hum. Mol. Genet. 19:1358-1367(2010).
RN   [13]
RP   FUNCTION.
RX   PubMed=22085962; DOI=10.1101/gad.173443.111;
RA   Wright K.J., Baye L.M., Olivier-Mason A., Mukhopadhyay S., Sang L.,
RA   Kwong M., Wang W., Pretorius P.R., Sheffield V.C., Sengupta P.,
RA   Slusarski D.C., Jackson P.K.;
RT   "An ARL3-UNC119-RP2 GTPase cycle targets myristoylated NPHP3 to the primary
RT   cilium.";
RL   Genes Dev. 25:2347-2360(2011).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS), INTERACTION WITH ARL3,
RP   CHARACTERIZATION OF VARIANTS RP2 HIS-118 AND GLY-138, AND CHARACTERIZATION
RP   OF VARIANT TRP-282.
RX   PubMed=16472755; DOI=10.1016/j.str.2005.11.008;
RA   Kuehnel K., Veltel S., Schlichting I., Wittinghofer A.;
RT   "Crystal structure of the human retinitis pigmentosa 2 protein and its
RT   interaction with Arl3.";
RL   Structure 14:367-378(2006).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1-350 OF COMPLEX WITH MOUSE ARL3
RP   AND GTP, FUNCTION, INTERACTION WITH ARL3, TISSUE SPECIFICITY,
RP   CHARACTERIZATION OF VARIANTS LEU-118 AND GLY-138, AND MUTAGENESIS OF
RP   SER-28; TRP-29; GLN-31; ARG-32; PHE-101; GLN-115; GLN-116; ARG-118; ARG-120
RP   AND PHE-177.
RX   PubMed=18376416; DOI=10.1038/nsmb.1396;
RA   Veltel S., Gasper R., Eisenacher E., Wittinghofer A.;
RT   "The retinitis pigmentosa 2 gene product is a GTPase-activating protein for
RT   Arf-like 3.";
RL   Nat. Struct. Mol. Biol. 15:373-380(2008).
RN   [16]
RP   VARIANT RP2 GLY-108.
RX   PubMed=10053026; DOI=10.1086/302298;
RA   Mears A.J., Gieser L., Yan D., Chen C., Fahrner S., Hiriyanna S.,
RA   Fujita R., Jacobson S.G., Sieving P.A., Swaroop A.;
RT   "Protein-truncation mutations in the RP2 gene in a North American cohort of
RT   families with X-linked retinitis pigmentosa.";
RL   Am. J. Hum. Genet. 64:897-900(1999).
RN   [17]
RP   VARIANT RP2 HIS-118.
RX   PubMed=10090907; DOI=10.1086/302325;
RA   Hardcastle A.J., Thiselton D.L., Van Maldergem L., Saha B.K., Jay M.,
RA   Plant C., Taylor R., Bird A.C., Bhattacharya S.;
RT   "Mutations in the RP2 gene cause disease in 10% of families with familial
RT   X-Linked retinitis pigmentosa assessed in this study.";
RL   Am. J. Hum. Genet. 64:1210-1215(1999).
RN   [18]
RP   VARIANTS RP2 SER-6 DEL AND HIS-118.
RX   PubMed=10520237; DOI=10.1076/opge.20.3.161.2278;
RA   Rosenberg T., Schwahn U., Feil S., Berger W.;
RT   "Genotype-phenotype correlation in X-linked retinitis pigmentosa 2 (RP2).";
RL   Ophthalmic Genet. 20:161-172(1999).
RN   [19]
RP   VARIANTS TRP-282 AND TYR-338.
RX   PubMed=10862093;
RX   DOI=10.1002/1098-1004(200006)15:6<580::aid-humu15>3.0.co;2-3;
RA   Thiselton D.L., Zito I., Plant C., Jay M., Hodgson S.V., Bird A.C.,
RA   Bhattacharya S.S., Hardcastle A.J.;
RT   "Novel frameshift mutations in the RP2 gene and polymorphic variants.";
RL   Hum. Mutat. 15:580-580(2000).
RN   [20]
RP   VARIANT RP2 ARG-253.
RX   PubMed=10634633;
RA   Wada Y., Nakazawa M., Abe T., Tamai M.;
RT   "A new Leu253Arg mutation in the RP2 gene in a Japanese family with X-
RT   linked retinitis pigmentosa.";
RL   Invest. Ophthalmol. Vis. Sci. 41:290-293(2000).
RN   [21]
RP   VARIANTS RP2 TYR-86; LEU-95; HIS-118 AND ILE-137 DEL, AND VARIANT TRP-282.
RX   PubMed=10937588;
RA   Sharon D., Bruns G.A.P., McGee T.L., Sandberg M.A., Berson E.L.,
RA   Dryja T.P.;
RT   "X-linked retinitis pigmentosa: mutation spectrum of the RPGR and RP2 genes
RT   and correlation with visual function.";
RL   Invest. Ophthalmol. Vis. Sci. 41:2712-2721(2000).
RN   [22]
RP   VARIANTS RP2 LEU-118 AND GLY-138, AND VARIANT TRP-282.
RX   PubMed=11462235; DOI=10.1002/humu.1160;
RA   Miano M.G., Testa F., Filippini F., Trujillo M., Conte I., Lanzara C.,
RA   Millan J.M., De Bernardo C., Grammatico B., Mangino M., Torrente I.,
RA   Carrozzo R., Simonelli F., Rinaldi E., Ventruto V., D'Urso M., Ayuso C.,
RA   Ciccodicola A.;
RT   "Identification of novel RP2 mutations in a subset of X-linked retinitis
RT   pigmentosa families and prediction of new domains.";
RL   Hum. Mutat. 18:109-119(2001).
RN   [23]
RP   VARIANTS RP2 TYR-67; HIS-118; ILE-137 DEL AND PRO-188, AND VARIANT TRP-282.
RX   PubMed=11992260; DOI=10.1086/340848;
RA   Breuer D.K., Yashar B.M., Filippova E., Hiriyanna S., Lyons R.H.,
RA   Mears A.J., Asaye B., Acar C., Vervoort R., Wright A.F., Musarella M.A.,
RA   Wheeler P., MacDonald I., Iannaccone A., Birch D., Hoffman D.R.,
RA   Fishman G.A., Heckenlively J.R., Jacobson S.G., Sieving P.A., Swaroop A.;
RT   "A comprehensive mutation analysis of RP2 and RPGR in a North American
RT   cohort of families with X-linked retinitis pigmentosa.";
RL   Am. J. Hum. Genet. 70:1545-1554(2002).
RN   [24]
RP   VARIANTS RP2 TYR-86; LEU-95; HIS-118 AND ILE-137 DEL, AND VARIANT TRP-282.
RX   PubMed=14564670; DOI=10.1086/379379;
RA   Sharon D., Sandberg M.A., Rabe V.W., Stillberger M., Dryja T.P.,
RA   Berson E.L.;
RT   "RP2 and RPGR mutations and clinical correlations in patients with X-linked
RT   retinitis pigmentosa.";
RL   Am. J. Hum. Genet. 73:1131-1146(2003).
RN   [25]
RP   VARIANTS RP2 HIS-118 AND CYS-118.
RX   PubMed=12657579; DOI=10.1167/iovs.02-0605;
RA   Bader I., Brandau O., Achatz H., Apfelstedt-Sylla E., Hergersberg M.,
RA   Lorenz B., Wissinger B., Wittwer B., Rudolph G., Meindl A., Meitinger T.;
RT   "X-linked retinitis pigmentosa: RPGR mutations in most families with
RT   definite X linkage and clustering of mutations in a short sequence stretch
RT   of exon ORF15.";
RL   Invest. Ophthalmol. Vis. Sci. 44:1458-1463(2003).
RN   [26]
RP   VARIANT RP2 TYR-108.
RX   PubMed=22334370; DOI=10.1002/humu.22045;
RA   Neveling K., Collin R.W., Gilissen C., van Huet R.A., Visser L.,
RA   Kwint M.P., Gijsen S.J., Zonneveld M.N., Wieskamp N., de Ligt J.,
RA   Siemiatkowska A.M., Hoefsloot L.H., Buckley M.F., Kellner U., Branham K.E.,
RA   den Hollander A.I., Hoischen A., Hoyng C., Klevering B.J.,
RA   van den Born L.I., Veltman J.A., Cremers F.P., Scheffer H.;
RT   "Next-generation genetic testing for retinitis pigmentosa.";
RL   Hum. Mutat. 33:963-972(2012).
RN   [27]
RP   VARIANT TRP-282.
RX   PubMed=27535533; DOI=10.1038/nature19057;
RG   Exome Aggregation Consortium;
RA   Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T.,
RA   O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T.,
RA   Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K., Zhao F., Zou J.,
RA   Pierce-Hoffman E., Berghout J., Cooper D.N., Deflaux N., DePristo M.,
RA   Do R., Flannick J., Fromer M., Gauthier L., Goldstein J., Gupta N.,
RA   Howrigan D., Kiezun A., Kurki M.I., Moonshine A.L., Natarajan P.,
RA   Orozco L., Peloso G.M., Poplin R., Rivas M.A., Ruano-Rubio V., Rose S.A.,
RA   Ruderfer D.M., Shakir K., Stenson P.D., Stevens C., Thomas B.P., Tiao G.,
RA   Tusie-Luna M.T., Weisburd B., Won H.H., Yu D., Altshuler D.M.,
RA   Ardissino D., Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C.,
RA   Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S., Laakso M.,
RA   McCarroll S., McCarthy M.I., McGovern D., McPherson R., Neale B.M.,
RA   Palotie A., Purcell S.M., Saleheen D., Scharf J.M., Sklar P.,
RA   Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C., Wilson J.G.,
RA   Daly M.J., MacArthur D.G.;
RT   "Analysis of protein-coding genetic variation in 60,706 humans.";
RL   Nature 536:285-291(2016).
CC   -!- FUNCTION: Acts as a GTPase-activating protein (GAP) involved in
CC       trafficking between the Golgi and the ciliary membrane. Involved in
CC       localization of proteins, such as NPHP3, to the cilium membrane by
CC       inducing hydrolysis of GTP ARL3, leading to the release of UNC119 (or
CC       UNC119B). Acts as a GTPase-activating protein (GAP) for tubulin in
CC       concert with tubulin-specific chaperone C, but does not enhance tubulin
CC       heterodimerization. Acts as a guanine nucleotide dissociation inhibitor
CC       towards ADP-ribosylation factor-like proteins.
CC       {ECO:0000269|PubMed:11847227, ECO:0000269|PubMed:18376416,
CC       ECO:0000269|PubMed:20106869, ECO:0000269|PubMed:22085962}.
CC   -!- SUBUNIT: Found in a complex with ARL3, RP2 and UNC119 (or UNC119B); RP2
CC       induces hydrolysis of GTP ARL3 in the complex, leading to the release
CC       of UNC119 (or UNC119B). Interacts with ARL3; interaction is direct and
CC       stimulated with the activated GTP-bound form of ARL3.
CC       {ECO:0000269|PubMed:11847227, ECO:0000269|PubMed:16472755,
CC       ECO:0000269|PubMed:18376416, ECO:0000269|PubMed:18588884}.
CC   -!- INTERACTION:
CC       O75695; Q8IYS1: PM20D2; NbExp=3; IntAct=EBI-7996807, EBI-11339910;
CC       O75695; Q9WUL7: Arl3; Xeno; NbExp=5; IntAct=EBI-7996807, EBI-6860857;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10942419,
CC       ECO:0000269|PubMed:12417528}; Lipid-anchor
CC       {ECO:0000269|PubMed:10942419}; Cytoplasmic side
CC       {ECO:0000269|PubMed:10942419}. Cell projection, cilium
CC       {ECO:0000269|PubMed:20106869}. Note=Detected predominantly at the
CC       plasma membrane of rod and cone photoreceptors. Not detected in the
CC       nucleus. {ECO:0000269|PubMed:12417528}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Expressed in the rod and cone
CC       photoreceptors, extending from the tips of the outer segment (OS)
CC       through the inner segment (IS) and outer nuclear layer (ONL) and into
CC       the synaptic terminals of the outer plexiform layer (ONL). Also
CC       detected in the bipolar, horizontal and amacrine cells in the inner
CC       nuclear layer (INL), extending to the inner plexiform layer (IPL) and
CC       though the ganglion cell layer (GCL) and into the nerve fiber layer
CC       (NFL) (at protein level). {ECO:0000269|PubMed:10942419,
CC       ECO:0000269|PubMed:12417528, ECO:0000269|PubMed:18376416}.
CC   -!- PTM: Myristoylated on Gly-2; which may be required for membrane
CC       targeting. {ECO:0000305|PubMed:10942419}.
CC   -!- PTM: Palmitoylated on Cys-3; which may be required for plasma membrane
CC       targeting (Probable). Mutation of Cys-3 targets the protein to internal
CC       membranes. {ECO:0000269|PubMed:10942419, ECO:0000305}.
CC   -!- DISEASE: Retinitis pigmentosa 2 (RP2) [MIM:312600]: A retinal dystrophy
CC       belonging to the group of pigmentary retinopathies. Retinitis
CC       pigmentosa is characterized by retinal pigment deposits visible on
CC       fundus examination and primary loss of rod photoreceptor cells followed
CC       by secondary loss of cone photoreceptors. Patients typically have night
CC       vision blindness and loss of midperipheral visual field. As their
CC       condition progresses, they lose their far peripheral visual field and
CC       eventually central vision as well. {ECO:0000269|PubMed:10053026,
CC       ECO:0000269|PubMed:10090907, ECO:0000269|PubMed:10520237,
CC       ECO:0000269|PubMed:10634633, ECO:0000269|PubMed:10937588,
CC       ECO:0000269|PubMed:10942419, ECO:0000269|PubMed:11462235,
CC       ECO:0000269|PubMed:11847227, ECO:0000269|PubMed:11992260,
CC       ECO:0000269|PubMed:12657579, ECO:0000269|PubMed:14564670,
CC       ECO:0000269|PubMed:16472755, ECO:0000269|PubMed:22334370,
CC       ECO:0000269|PubMed:9697692}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the TBCC family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ007590; CAA07577.1; -; mRNA.
DR   EMBL; AL050307; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL627143; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC043348; AAH43348.1; -; mRNA.
DR   EMBL; BC053530; AAH53530.1; -; mRNA.
DR   CCDS; CCDS14270.1; -.
DR   RefSeq; NP_008846.2; NM_006915.3.
DR   PDB; 2BX6; X-ray; 2.10 A; A=1-350.
DR   PDB; 3BH6; X-ray; 2.60 A; B=1-350.
DR   PDB; 3BH7; X-ray; 1.90 A; B=1-350.
DR   PDBsum; 2BX6; -.
DR   PDBsum; 3BH6; -.
DR   PDBsum; 3BH7; -.
DR   AlphaFoldDB; O75695; -.
DR   BMRB; O75695; -.
DR   SMR; O75695; -.
DR   BioGRID; 112029; 140.
DR   CORUM; O75695; -.
DR   DIP; DIP-29024N; -.
DR   ELM; O75695; -.
DR   FunCoup; O75695; 1417.
DR   IntAct; O75695; 93.
DR   MINT; O75695; -.
DR   STRING; 9606.ENSP00000218340; -.
DR   GlyGen; O75695; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O75695; -.
DR   PhosphoSitePlus; O75695; -.
DR   SwissPalm; O75695; -.
DR   BioMuta; RP2; -.
DR   jPOST; O75695; -.
DR   MassIVE; O75695; -.
DR   PaxDb; 9606-ENSP00000218340; -.
DR   PeptideAtlas; O75695; -.
DR   ProteomicsDB; 50167; -.
DR   Pumba; O75695; -.
DR   Antibodypedia; 373; 166 antibodies from 26 providers.
DR   DNASU; 6102; -.
DR   Ensembl; ENST00000218340.4; ENSP00000218340.3; ENSG00000102218.7.
DR   GeneID; 6102; -.
DR   KEGG; hsa:6102; -.
DR   MANE-Select; ENST00000218340.4; ENSP00000218340.3; NM_006915.3; NP_008846.2.
DR   UCSC; uc004dgw.5; human.
DR   AGR; HGNC:10274; -.
DR   ClinPGx; PA34641; -.
DR   CTD; 6102; -.
DR   DisGeNET; 6102; -.
DR   GeneCards; RP2; -.
DR   GeneReviews; RP2; -.
DR   HGNC; HGNC:10274; RP2.
DR   HPA; ENSG00000102218; Tissue enhanced (bone).
DR   MalaCards; RP2; -.
DR   MIM; 300757; gene.
DR   MIM; 312600; phenotype.
DR   OpenTargets; ENSG00000102218; -.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   VEuPathDB; HostDB:ENSG00000102218; -.
DR   eggNOG; KOG2512; Eukaryota.
DR   GeneTree; ENSGT00940000158262; -.
DR   HOGENOM; CLU_056119_0_0_1; -.
DR   InParanoid; O75695; -.
DR   OMA; KDYMLTG; -.
DR   OrthoDB; 194775at2759; -.
DR   PAN-GO; O75695; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; O75695; -.
DR   PathwayCommons; O75695; -.
DR   Reactome; R-HSA-5624138; Trafficking of myristoylated proteins to the cilium.
DR   SignaLink; O75695; -.
DR   Agora; ENSG00000102218; -.
DR   BioGRID-ORCS; 6102; 17 hits in 778 CRISPR screens.
DR   ChiTaRS; RP2; human.
DR   EvolutionaryTrace; O75695; -.
DR   GeneWiki; RP2_(gene); -.
DR   GenomeRNAi; 6102; -.
DR   Pharos; O75695; Tbio.
DR   PRO; PR:O75695; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O75695; protein.
DR   Bgee; ENSG00000102218; Expressed in monocyte and 165 other cell types or tissues.
DR   ExpressionAtlas; O75695; baseline and differential.
DR   GO; GO:0001669; C:acrosomal vesicle; IDA:HPA.
DR   GO; GO:0005814; C:centriole; IEA:Ensembl.
DR   GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB.
DR   GO; GO:0005929; C:cilium; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IGI:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:1990075; C:periciliary membrane compartment; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097229; C:sperm end piece; IDA:HPA.
DR   GO; GO:0097225; C:sperm midpiece; IDA:HPA.
DR   GO; GO:0097228; C:sperm principal piece; IDA:HPA.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:ProtInc.
DR   GO; GO:0060271; P:cilium assembly; TAS:Reactome.
DR   GO; GO:0006892; P:post-Golgi vesicle-mediated transport; IMP:MGI.
DR   GO; GO:0006457; P:protein folding; TAS:UniProtKB.
DR   GO; GO:0015031; P:protein transport; IEA:UniProtKB-KW.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   FunFam; 2.160.20.70:FF:000004; Protein XRP2; 1.
DR   FunFam; 3.30.70.141:FF:000007; Protein XRP2; 1.
DR   Gene3D; 2.160.20.70; -; 1.
DR   Gene3D; 3.30.70.141; Nucleoside diphosphate kinase-like domain; 1.
DR   InterPro; IPR017901; C-CAP_CF_C-like.
DR   InterPro; IPR016098; CAP/MinC_C.
DR   InterPro; IPR036223; CAP_C_sf.
DR   InterPro; IPR006599; CARP_motif.
DR   InterPro; IPR036850; NDK-like_dom_sf.
DR   InterPro; IPR012945; Tubulin-bd_cofactor_C_dom.
DR   InterPro; IPR039093; XRP2.
DR   PANTHER; PTHR15440:SF0; PROTEIN XRP2; 1.
DR   PANTHER; PTHR15440; XRP2 PROTEIN; 1.
DR   Pfam; PF07986; TBCC; 1.
DR   PIRSF; PIRSF037947; Protein_XRP2; 1.
DR   SMART; SM00673; CARP; 2.
DR   SUPFAM; SSF69340; C-terminal domain of adenylylcyclase associated protein; 1.
DR   SUPFAM; SSF54919; Nucleoside diphosphate kinase, NDK; 1.
DR   PROSITE; PS51329; C_CAP_COFACTOR_C; 1.
DR   PROSITE; PS51374; NDPK_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cell projection; Cilium; Disease variant;
KW   GTP-binding; GTPase activation; Lipoprotein; Membrane; Myristate;
KW   Nucleotide-binding; Palmitate; Protein transport;
KW   Proteomics identification; Reference proteome; Retinitis pigmentosa;
KW   Transport.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:25255805"
FT   CHAIN           2..350
FT                   /note="Protein XRP2"
FT                   /id="PRO_0000080047"
FT   DOMAIN          24..179
FT                   /note="C-CAP/cofactor C-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00659"
FT   REGION          1..31
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..10
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        11..31
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         98..99
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT   BINDING         115..118
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000305|PubMed:10942419"
FT   LIPID           3
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000305|PubMed:10942419"
FT   VARIANT         6
FT                   /note="Missing (in RP2; loss of membrane association;
FT                   enhances interaction with ARL3; dbSNP:rs137852284)"
FT                   /evidence="ECO:0000269|PubMed:10520237,
FT                   ECO:0000269|PubMed:10942419, ECO:0000269|PubMed:11847227,
FT                   ECO:0000269|PubMed:9697692"
FT                   /id="VAR_008497"
FT   VARIANT         67
FT                   /note="C -> Y (in RP2; dbSNP:rs2147081192)"
FT                   /evidence="ECO:0000269|PubMed:11992260"
FT                   /id="VAR_018069"
FT   VARIANT         86
FT                   /note="C -> Y (in RP2; dbSNP:rs2147081236)"
FT                   /evidence="ECO:0000269|PubMed:10937588,
FT                   ECO:0000269|PubMed:14564670"
FT                   /id="VAR_018070"
FT   VARIANT         95
FT                   /note="P -> L (in RP2; uncertain significance;
FT                   dbSNP:rs2147081255)"
FT                   /evidence="ECO:0000269|PubMed:10937588,
FT                   ECO:0000269|PubMed:14564670"
FT                   /id="VAR_018071"
FT   VARIANT         108
FT                   /note="C -> G (in RP2)"
FT                   /evidence="ECO:0000269|PubMed:10053026"
FT                   /id="VAR_008498"
FT   VARIANT         108
FT                   /note="C -> Y (in RP2)"
FT                   /evidence="ECO:0000269|PubMed:22334370"
FT                   /id="VAR_068353"
FT   VARIANT         118
FT                   /note="R -> C (in RP2; dbSNP:rs1556318633)"
FT                   /evidence="ECO:0000269|PubMed:12657579"
FT                   /id="VAR_026058"
FT   VARIANT         118
FT                   /note="R -> H (in RP2; reduces affinity for ARL3 800-fold;
FT                   loss of stimulation of tubulin GTPase activity; no effect
FT                   on subcellular location; dbSNP:rs28933687)"
FT                   /evidence="ECO:0000269|PubMed:10090907,
FT                   ECO:0000269|PubMed:10520237, ECO:0000269|PubMed:10937588,
FT                   ECO:0000269|PubMed:10942419, ECO:0000269|PubMed:11847227,
FT                   ECO:0000269|PubMed:11992260, ECO:0000269|PubMed:12657579,
FT                   ECO:0000269|PubMed:14564670, ECO:0000269|PubMed:16472755,
FT                   ECO:0000269|PubMed:9697692"
FT                   /id="VAR_008499"
FT   VARIANT         118
FT                   /note="R -> L (in RP2; dbSNP:rs28933687)"
FT                   /evidence="ECO:0000269|PubMed:11462235,
FT                   ECO:0000269|PubMed:18376416"
FT                   /id="VAR_018072"
FT   VARIANT         137
FT                   /note="Missing (in RP2; dbSNP:rs1924904597)"
FT                   /evidence="ECO:0000269|PubMed:10937588,
FT                   ECO:0000269|PubMed:11992260, ECO:0000269|PubMed:14564670"
FT                   /id="VAR_018073"
FT   VARIANT         138
FT                   /note="E -> G (in RP2; reduces affinity for ARL3 150-fold
FT                   and inhibits the GTP-hydrolysis rate of ARL3)"
FT                   /evidence="ECO:0000269|PubMed:11462235,
FT                   ECO:0000269|PubMed:16472755, ECO:0000269|PubMed:18376416"
FT                   /id="VAR_018074"
FT   VARIANT         144
FT                   /note="K -> R (in dbSNP:rs3126141)"
FT                   /id="VAR_053961"
FT   VARIANT         188
FT                   /note="L -> P (in RP2)"
FT                   /evidence="ECO:0000269|PubMed:11992260"
FT                   /id="VAR_018075"
FT   VARIANT         253
FT                   /note="L -> R (in RP2; dbSNP:rs2147081596)"
FT                   /evidence="ECO:0000269|PubMed:10634633"
FT                   /id="VAR_008500"
FT   VARIANT         282
FT                   /note="R -> W (reduces affinity for ARL3 3-fold;
FT                   dbSNP:rs1805147)"
FT                   /evidence="ECO:0000269|PubMed:10862093,
FT                   ECO:0000269|PubMed:10937588, ECO:0000269|PubMed:11462235,
FT                   ECO:0000269|PubMed:11992260, ECO:0000269|PubMed:14564670,
FT                   ECO:0000269|PubMed:16472755, ECO:0000269|PubMed:27535533"
FT                   /id="VAR_014535"
FT   VARIANT         338
FT                   /note="D -> Y (in dbSNP:rs1805148)"
FT                   /evidence="ECO:0000269|PubMed:10862093"
FT                   /id="VAR_014536"
FT   MUTAGEN         2
FT                   /note="G->A: Loss of membrane association."
FT                   /evidence="ECO:0000269|PubMed:10942419"
FT   MUTAGEN         3
FT                   /note="C->S: Targeting to internal membranes. Loss of
FT                   targeting to the plasma membrane."
FT                   /evidence="ECO:0000269|PubMed:10942419"
FT   MUTAGEN         28
FT                   /note="S->A: Reduces affinity for mouse ARL3; when
FT                   associated with A-29."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         29
FT                   /note="W->A: Reduces affinity for mouse ARL3; when
FT                   associated with A-28."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         31
FT                   /note="Q->A: Does not reduce affinity for mouse ARL3; when
FT                   associated with A-32."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         32
FT                   /note="R->A: Does not reduce affinity for mouse ARL3; when
FT                   associated with A-31."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         101
FT                   /note="F->A: Reduces affinity for mouse ARL3."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         115
FT                   /note="Q->A: Reduces affinity for mouse ARL3."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         116
FT                   /note="Q->A: Reduces affinity and GTP-hydrolysis rate for
FT                   mouse ARL3."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         118
FT                   /note="R->A: Reduces affinity and GTP-hydrolysis rate for
FT                   mouse ARL3."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         120
FT                   /note="R->H: Reduces affinity for mouse ARL3; when
FT                   associated with S-121."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   MUTAGEN         121
FT                   /note="D->S: Reduces affinity for mouse ARL3; when
FT                   associated with H-120."
FT   MUTAGEN         177
FT                   /note="F->A: Reduces affinity and GTP-hydrolysis rate for
FT                   mouse ARL3."
FT                   /evidence="ECO:0000269|PubMed:18376416"
FT   CONFLICT        168
FT                   /note="N -> D (in Ref. 1; CAA07577)"
FT                   /evidence="ECO:0000305"
FT   STRAND          39..44
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          49..52
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          62..66
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          71..74
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          81..85
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          90..104
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          106..121
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          123..133
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          136..139
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          141..147
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           155..161
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          175..178
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          185..188
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           195..197
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           205..207
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   TURN            216..218
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          235..240
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           246..259
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          263..270
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           274..281
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           282..287
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           289..294
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          297..304
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           307..318
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   STRAND          324..326
FT                   /evidence="ECO:0007829|PDB:3BH7"
FT   HELIX           330..348
FT                   /evidence="ECO:0007829|PDB:3BH7"
SQ   SEQUENCE   350 AA;  39641 MW;  3C912B52C53A817E CRC64;
     MGCFFSKRRK ADKESRPENE EERPKQYSWD QREKVDPKDY MFSGLKDETV GRLPGTVAGQ
     QFLIQDCENC NIYIFDHSAT VTIDDCTNCI IFLGPVKGSV FFRNCRDCKC TLACQQFRVR
     DCRKLEVFLC CATQPIIESS SNIKFGCFQW YYPELAFQFK DAGLSIFNNT WSNIHDFTPV
     SGELNWSLLP EDAVVQDYVP IPTTEELKAV RVSTEANRSI VPISRGQRQK SSDESCLVVL
     FAGDYTIANA RKLIDEMVGK GFFLVQTKEV SMKAEDAQRV FREKAPDFLP LLNKGPVIAL
     EFNGDGAVEV CQLIVNEIFN GTKMFVSESK ETASGDVDSF YNFADIQMGI
//
